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Abstract The standard of care in bone metastases is antire-
sorptive therapy. If present in the bone, tumor cells induce a
vicious cycle by stimulating the osteoclasts, which further
accelerates tumor progression. The widely-used bisphospho-
nates or the new therapeutic option, denosumab an inhibitor of
the receptor activator of NF-κB ligand (RANKL), interrupt
this vicious cycle, inhibit tumor growth, and in clinical prac-
tice prevent skeleton-related events. Adjuvant oncological
therapy, including chemotherapy and endocrine manipula-
tions (ovarian ablation and tamoxifen in premenopausal, and
aromatase inhibitors in postmenopausal women), increases
the bone turnover and the risk of fracture. Awareness is
essential for the diagnosis and treatment of cancer therapy-
induced bone loss, or its prevention with appropriate calcium
and vitamin D supplementation. A new possibility has been
suggested for the prevention of relapse: the use of bisphosph-
onates in the adjuvant setting. Three large studies and their
meta-analyses indicate that the inhibition of bone remodeling
prevents the growth of dormant tumor cells and cancer relapse
in the population of postmenopausal patients with a low-
estrogen environment in the skeleton. The similar potential
of a RANKL inhibitor is currently under evaluation. Since the
maintenance of bone integrity is necessary for the prevention
of both therapy-related side-effects and progression of the
disease, the management of breast cancer at any stage requires
a careful consideration of the bone homeostasis.
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Introduction
Since patients with breast cancer are at an increased risk of
skeletal complications throughout the course of their dis-
ease, attention must be paid to maintaining the bone homeo-
stasis. Interventions may promote the prevention of both
therapy-related adverse events and tumor relapse. Thus,
the everyday functioning, the quality of life, the cancer-
free status and health economics are concerned when the
topic of bone integrity is considered.
Anti-Bone Remodeling Therapy in Bone Metastasis
Around 70 % of advanced-stage breast cancer patients de-
velop bone metastases. If these remain without therapy, they
may result in debilitating skeletal events and a significant
deterioration in the quality of life. Great advances have been
achieved in the management of bone metastasis in breast
cancer: since bisphosphonates and (more recently) denosu-
mab an inhibitor of the receptor activator of the NF-κB
ligand (RANKL), i.e. the bone-modifying agents, were
shown to interact with both bone destruction and tumor
progression, they have become an integral component of
the complex therapy of bone metastases [1].
The development of tumor metastases in the skeleton is a
complex multistep process. For tumor cell colonies to un-
dergo successful implantation, a cross-talk between bone-
resorbing osteoclasts and cancer cells is critical for the
emergence of a microenvironment (the metastatic niche)
suitable for acceptance of the micrometastases in the bone.
In this abnormal microenvironment, the balance between the
participants of the bone homeostasis is altered. A vicious
cycle arises, and the bone and tumor cells mutually stimu-
late each other, which results in progression of the bone
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metastases and bone remodeling. The recruitment and mat-
uration of the osteoclasts is upregulated, though their attach-
ment to the bone surface is critical for bone degradation.
This also leads to activation of the osteoblasts. In bone
metastases, therefore, enhanced remodeling takes place
while the bone resorption and calcification are both activat-
ed. Bone metastases in breast cancer are osteolytic rather
than osteoblastic. Among various osteolytic cytokines, the
parathormone-related peptide has a crucial role in the path-
omechanism of bone metastasis, since it stimulates the se-
cretion of the RANKL responsible for osteoclast activation
(Table 1) [2–4].
The recent progress in the understanding of the biological
mechanism of bone metastasis led to the development of
specific bone-targeted therapies that inhibit bone resorption.
Bisphosphonates bind to the bone surface, and exert a direct
toxic effect on the osteoclasts. The humanized RANKL
antibody inhibits osteoclastogenesis by selectively targeting
and neutralizing the RANKL.
The family of bisphosphonates contains molecules in-
volving a P-C-P chain linked to variable side- chains, with
different affinities for bone and different modes of action as
regards osteoclast inhibition (Fig. 1, Table 2). In the bone,
bisphosphonates bound to hydroxyapatite inhibit the disso-
lution of calcium phosphate and the activity of the osteo-
clasts. After their endocytosis, the bisphosphonates interact
with various intracellular enzymatic steps. The mode of
action depends on the type of the bisphosphonate: non-
nitrogen-containing bisphosphonates are metabolized to cy-
totoxic nucleotide analogs in the osteoclasts, while nitrogen-
containing bisphosphonates inhibit farnesyl pyrophosphate
synthase which is responsible for the prenylation of GTP-
ases. Nitrogen-containing bisphosphonates inhibit mature
osteoclasts and the migration and evolution of the premature
osteoclasts. Although bisphosphonates inhibit enzymes that
are present in all cells, their toxic effect is limited to osteo-
clasts because these cells accumulate bisphosphonates in
sufficiently high concentration [5].
Table 1 Mediators that play a role in the vicious cycle that stimulates bone remodeling [2–4]
Mediator Source/localization Activity
VEGF-A tumor cells stimulates angiogenesis
FGF-1, FGF-2 stored in extracellular matrix stimulates angiogenesis
VEGF-C, VEGF-D tumor cells stimulates lymphangiogenesis
M-CSF mesenchymal stem cells, tumor cells stimulates osteoclastogenesis
RANKL osteoblasts enhances the maturation, migration and activation of osteoclasts
PTHrP tumor cells increases the expression of RANKL
decreases the expression of OPG
IGF-1 bone mass enhances tumor cell proliferation, increases chemotaxis, prevents
apoptosis
TGF-β bone mass enhances the production of PTHrP in tumor cells
PDGF platelets enhances tumor cell proliferation
BMP bone mass enhances tumor cell proliferation
OPN,BSP, vitronectin,
collagen type-1
bone mass increases tumor cell homing to bone
integrins surface of tumor cells increases tumor extravasation and binding to bone extracellular matrix
(OPN, BSP, vitronectin)
SDF1 bone marrow increases tumor cell homing to bone via interaction with CXCR4 receptor
on tumor surface
IL-1 monocytes/macrophages increases the expression of IL-6 and IL-11 in osteoblasts
IL-3 activated T-cells, macrophages enhances the maturation of osteoclasts
IL-6, IL-11 osteoblasts, bone marrow stromal cells,
tumor cells
enhances the maturation of osteoclasts
TNF-α,-β monocytes/macrophages increases the expression of IL-6 and IL-11 in osteoblasts
MMPs extracellular matrix, tumor cells increases tumor invasion and migration
cadherin-11, N-cadherin cell membrane increases tumor invasion and migration
E-cadherin cell membrane loss of E-cadherin is essential for tumor spreading
OPG osteoblasts, hematopoietic cells decoy receptor for RANKL, decreased level of OPG!
VEGF vascular endothelial growth factor; FGF fibroblast growth factor; M-CSF macrophage colony stimulating factor; RANKL receptor activator
of NF-κB ligand; PTHrP parathyroid hormone-related protein; IGF insulin-like growth factor; TGF-β transforming growth factor; PDGF platelet-
derived growth factor; BMP bone morphogenetic protein; OPN osteopontin; BSP bone sialoprotein; SDF1 stromal cell-derived factor 1; IL
interleukin; TNF tumor necrosis factor, MMP matrix metalloproteinase; OPG osteoprotegerin
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The following effects exerted by bisphosphonates result
in disruption of the vicious cycle in bone metastasis [6, 7]:
– They decrease the number of osteoclasts;
– They inhibit the binding of osteoclasts to the bone
surface;
– They downregulate the expression of RANK in
osteoclasts;
– They inhibit tumor cell adhesion to the bone surface;
– They inhibit angiogenesis; and
– They act synergistically with chemotherapy.
The absorption of oral bisphosphonates (only 1 %) is
limited by the high pH in the small intestine. Their plasma
concentration rapidly decreases within 1 h, and they bind to
bone, especially where intense bone remodeling is taking
place. Bisphosphonates are not metabolized, and are elimi-
nated by the skeleton and the kidneys. Their half-lives are
many years. Since the clearance of bisphosphonates
depends on the kidney function, the dose must be modified
accordingly (Fig. 2) [8]. Adverse effects are rare, and may
be prevented by close surveillance (Table 3) [9].
A number of clinical studies have demonstrated the po-
tential of bisphosphonates in the complex therapy of breast
cancer bone metastases. Ross et al. reviewed 30 randomized
trials in which bone metastatic breast cancer patients were
treated with bisphosphonates. The administration of
bisphosphonates for at least 6 months significantly reduced
the occurrence of skeleton-related events (SREs), including
fracture, the need for radiotherapy or surgery or myelon com-
pression or hypercalcemia due to bone metastasis [10]. The
meta-analysis of 9 randomized studies of 2,806 cases in which
the bisphosphonate arm was compared with a control arm
showed that bisphosphonates can reduce the risk of a SRE by
15 % (RR00.85; 95 % CI 0.77–0.94; p00.001) [11]. The use
of bisphosphonates resulted in better pain reduction and an
improved quality of life [12]. No effect on survival was dem-
onstrated. Intravenously administered nitrogen-containing
bisphosphonates are superior in preventing a SRE, and the
most potent of all known bisphosphonates is zoledronate, a
third-generation intravenous bisphosphonate (RR00.59; 95 %
CI 0.42–0.82) [11]. Two studies indicated the beneficial effects
of reduced bone resorption and pain when the treatment of
patients with progressive bone metastases or SREs was
changed from clodronate to a third-generation bisphosphonate
(ibandronate or zoledronate) [13, 14]. Bisphosphonates are
generally well-tolerated; rare complications may be prevented
by awareness of the possibility of a renal impairment or osteo-
necrosis of the jaw (Table 3) [1, 9, 15].
Denosumab is a fully humanized monoclonal IgG2 anti-
body that targets the RANKL, and provides an alternative
method for the treatment of breast cancer bone metastases
[16]. While the bisphosphonates interact with intracellular
processes of the ostoclasts, denosumab blocks the extracellular
process of RANK/RANKL signal transduction. The RANKL,
Fig. 1 Bisphosphonates: formation and structure
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produced by the osteoblasts, is a member of the TNF family,
and enhances the maturation, migration and activity of osteo-
clasts. After binding to the RANKL, denosumab neutralizes it,
thereby inhibiting bone resorption by blocking premature and
mature osteoclasts [17]. Denosumab is administered as a sub-
cutaneous injection. After its rapid absorption, the peak plasma
concentration (Cmax) is obtained after 7–14 days. Complete
elimination by the reticuloendothelial system (as in the case of
other antibodies) takes around 6 months, and is not influenced
by the renal or hepatic function. If there is a renal insufficiency,
the serum calcium level should be monitored. No antibody
against denosumab is produced after its administration. [18]
In a large phase III study involving 2,046 breast cancer
cases with bone metastases, denosumab was tested against
intravenous zoledronate. Denosumab significantly delayed
the time to the first (HR00.82, p00.01) or subsequent SREs
(HR00.77, p00.001). No difference in overall survival or
disease progression was found between the treatment arms.
While significantly more chills, pyrexia, bone pain and
arthralgia occurred in the zoledronate arm, more hypocalce-
mia developed among the denosumab-treated patients [19].
During denosumab therapy, vigilance is needed in order to
the prevent hypocalcemia, especially in patients with an
impaired renal function (Tables 3 and 4) [1]. The study
Table 2 Structure-activity relationship of bisphosphonates
Structure Activity 
binds to bone and enzymes (farnesyl 
pyrophosphate synthase, aminoacyl-
tRNA synthases)
P-C-P metabolic and kinetic stability 
R1:  
- hydroxy 
chemical variability 
- increased binding affinity to bone  
R2:  
- methyl or chloro 
- nitrogen-containing side-chain  
chemical variability 
-inhibition of mitochondrial ATP 
metabolism (clodronate, etidronate) 
- improved inhibition of farnesyl 
pyrophosphate synthase and 
antiresorptive effect 
primary amine alendronate, pamidronate 
tertiary amine ibandronate 
pyridine risedronate 
imidazole zoledronate  
Bisphosphonates
Binding to bone Elimination via the kidneys
Uptake by the osteoclasts Release from the bone
Binding to bone again Elimination via the kidneys
Fig. 2 The metabolism of
bisphosphonates
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contributed to the registration of denosumab for the preven-
tion of SRE in bone metastatic solid tumors. Long-term
efficacy and safety data are awaited.
In conclusion, anti-bone remodeling therapy with
bisphosphonates or with denosumab is recommended for
breast cancer patients with bone metastases. All such patients
should be examined at the commencement of therapy, and
regularly monitored thereafter for maintenance of the optimal
level of oral health and renal function. The follow-up of bio-
chemical markers of bone remodeling is not justified (Table 4).
The Prevention of Adjuvant Breast Cancer
Therapy-Induced Bone Loss
Adjuvant therapy, including adjuvant endocrine therapy and
chemotherapy, is extensively applied postoperatively with
curative intent. Both forms of intervention increase the risk
of bone loss and bone fracture [20].
Since estrogens play a key role in the development and
progression of hormone-sensitive breast cancer, the com-
mon goal of the currently applied endocrine manipulations
is estrogen deprivation, either by competitive blockade of
the hormone at the level of its receptor or by inhibition of its
synthesis. Adjuvant endocrine therapy lasts for many years,
and there is therefore sufficient time for the development of
side-effects and long-term sequelae of the therapy.
Osteoporosis, a progressive natural process associated with
a yearly 1 % decrease in bone mineral density (BMD) and a
higher risk of fracture in postmenopausal women, is acceler-
ated by an estrogen deficiency. Tamoxifen exerts differential
effects on the BMD, depending on the menopausal status: in
premenopausal women, it causes a significant lowering of the
BMD, whereas in postmenopausal patients it improves both
Table 3 Possible toxic effects
of bisphosphonates and their
prevention
BPs bisphosphonates, iv
intravenous
Adverse event Risk reduction Risk factor
- nausea, vomiting,
dyspepsia (oral BPs)
oral administration: instructions
for administration or change
for intravenous administration
anamnestic GI hemorrhage,
peptic ulcer, Barrett
esophagus- esophagitis, esophageal
erosion (oral BPs)
- esophageal cancer (oral BPs)
- conjunctivitis (iv. BPs) mild and transient; all
ophthalmic symptoms
should be monitored
- uveitis, iriditis (iv. BPs)
- renal toxicity (iv. BPs) kidney function should be
regularly monitored
chemotherapy, diabetes,
previous kidney lesion
- hypocalcemia (iv. or oral BPs) serum Ca monitoring
- acute phase reaction
(only iv. nitrogen-containing BPs)
paracetamol therapy
- atrial fibrillation follow-up of patients at risk
- muscle pain
- osteonecrosis of the jaw (ONJ) avoidance of invasive
dental intervention
poor oral hygiene
- atypical fracture
Table 4 ASCO guidelines on the role of bone-modifying agents (BMAs) in metastatic breast cancer [1]
• BMAs are recommended for patients with metastatic breast cancer with evidence of bone destruction
• Denosumab 120 mg subcutaneously every 4 weeks; intravenous pamidronate 90 mg over no less than 2 h
every 3 to 4 weeks; or intravenous zoledronic acid 4 mg over no less than 15 min every 3 to 4 weeks
• One BMA is not recommended over another
• In patients with a creatinine clearance of 60 mL/min, no change in dosage, infusion time or interval is required;
the creatinine level is monitored for each intravenous bisphosphonate dose
• In patients with a creatinine clearance of 30 mL/min or on dialysis who may be treated with denosumab,
close monitoring for hypocalcemia is recommended
• All patients should have a dental examination and preventive dentistry before using a BMA
• At the onset of cancer bone pain, the standard of care for pain management should be provided and BMAs should be started
• The use of biochemical markers to monitor BMA use is not recommended for routine care
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spongious (spine) and compact (hip) bone formation [21].
Significant increases in BMD were demonstrated in different
studies after the administration of tamoxifen to postmenopaus-
al breast cancer patients [22, 23].
Adjuvant aromatase inhibitor (AI) therapy brings about a
long-lasting significant deprivation of circulatory and tissue
estrogens. As a result, the fall in BMD is enhanced to about
2.5 % per year [24, 25]. In the bone subprotocol of the ATAC
study, patients treated with anastrozole exhibited significant
decreases in BMD (~ 4 %), whereas those treated with tamox-
ifen displayed significant BMD increases of 1.2 % and 2.2 %
in the lumbar and hip areas, respectively [25]. Significantly
more new osteoporosis was observed among the AI-treated
women in the IES and MA. 17 trials [25–27]. In the adjuvant
AI studies, fracture rates were consistently elevated in the AI
arms as comparedwith the tamoxifen arms, but the differences
disappeared after the termination of therapy in the ATAC
study [28].
Ovarian ablation, achieved either surgically or medically,
causes a significant depletion of sex hormones in premeno-
pausal women. The application of LHRH analogs results in
transient, but complete ovarian hormone ablation, which is
usuallymaintained for up to 2–3 years. In the bone subprotocol
of the ZEBRA study, the mean BMD losses in premenopausal
patients treated with goserelin for 2 years were 10.5 % and
6.4 % for the lumbar spine and femoral neck, respectively. At
3 years, in contrast with the situation after CMF (cyclophos-
phamide, methotrexate and 5-fluorouracil) chemotherapy, a
partial recovery was seen [29]. Chemotherapy-induced amen-
orrhea develops in a transient or definitive manner, depending
on the age of the patient and the regimen applied [20]. The
impact of chemotherapy on bone loss is probably mediated
mostly by ovarian ablation, though the direct effects of cyto-
static agents on the bone homeostasis can not be excluded.
Arthralgia is a typical adverse event of estrogen depriva-
tion that is most significant during AI therapy. The arthralgia
syndrome includes not only joint pain, but also myalgia,
fibromyalgia or neuropathy, and its incidence may be as
high as 50 % among patients on AI therapy [30, 31]. This
syndrome results in a decreased mobility of the patient,
another factor enhancing the risk of increased bone loss.
The available data suggest that bisphosphonates have the
potential to prevent bone loss during adjuvant breast cancer
therapy [32] (Table 5). The oral bisphosphonate risedronate
has been found to be effective in preventing chemotherapy-
induced bone loss in premenopausal women [33]. In the Z-
FAST study, 602 postmenopausal patients receiving adjuvant
letrozole therapy were randomized to upfront vs. delayed
zoledronate therapy (in the delayed group therapy was started
if the BMD decreased to −2.0) [36]. In the companion studies
ZO-FAST and E-ZO-FAST, similar results were found, de-
spite the fact that the 3 studies included patients from different
geographical areas [37, 38]. In the ABCSG-12 trial, the BMD
was studied in premenopausal women treated with goserelin
and either tamoxifen or anastrozole, with or without zoledro-
nate. During the administration of goserelin plus tamoxifen or
anastrozole as adjuvant hormone therapy for 3 years, the
BMD of the lumbar spine decreased by 9.0 % (tamoxifen)
or by 13.6 % (anastrozole) in the absence of bisphosphonate
therapy. Although the BMD of the lumbar spine had to some
extent recovered 2 years after the discontinuation of therapy, it
was still below the baseline in both groups, despite the fact
Table 5 Studies for the prevention of adjuvant therapy-induced bone loss
Patients Oncological therapy Bisphosphonate BMD change
Delmas et al. 1997 [33] n053, premeno chemotherapy risedronate 35 mg/week
vs. placebo
0.3 vs. −1.4 % per year
Lester 2007, ARIBON [34] n0131, postmeno anastrozole ibandronate vs. placebo 2.8 vs. −2.6 % per year
Gnant 2011, ABCSG-12
subgroup [35]
n0401, premeno goserelin + anastrozole
or goserelin + tamoxifen
zoledronate 4 mg/
6 months vs. nil
NC vs. −17.4
or −11.6 % per 3 years
Brufsky 2011, Z-FAST [36] n0602 letrozole zoledronate 4 mg/6 months
upfront vs. delayed
1.9 vs. −2.5 % per year
Eidtmann 2009,
ZO-FAST [37]
n01066 letrozole zoledronate 4 mg/6 months
upfront vs. delayed
4.4 vs. −4.9 % per 5 years
Llombart 2012,
E-ZO-FAST [38]
n0527 letrozole zoledronate 4 mg/6 months
upfront vs. delayed
2.7 vs. −2.7 % per year
Hines 2009, N03CC [35] n0395 extended adjuvant
letrozole
zoledronate 4 mg/6 months
upfront vs. delayed
3.7 vs. −1.7 % per year
van Poznak 2010,
SABRE [39]
n0111 anastrozole risedronate 35 mg/
week vs. placebo
significant increase vs.
decrease in 3 risk
groups
Ellis 2008, HALT-BC [40] n0252 aromatase inhibitor denosumab 60 mg/
6 months vs. placebo
6.2 vs. −1.4 % per 2 years
BMD bone mineral density
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that three-quarters of the patients had regained menses [35,
41–43]. Similarly, a significantly increased BMDwas attained
in the N03CC study, in which zoledronate was applied togeth-
er with extended adjuvant letrozole therapy after 5 years of
tamoxifen [39], and in the SABRE study, in which risedronate
was applied together with anastrozole, as compared with these
endocrine agents together with placebo [40]. In the Hormone
Ablation Bone Loss Trial in Breast Cancer (HALT-BC) study,
denosumab administered to patients on adjuvant AI therapy
twice a year resulted in consistent increases in BMD at 12 and
24 months as compared with the placebo group [44].
A decreased BMD is the most important factor leading to
an enhanced risk of fracture, an event with serious consequen-
ces to personal life and health economics. Other clinical risk
factors, such as a reduced body mass index (BMI), a family or
personal history of fracture, the use of corticosteroids and
smoking should also be assessed prior to the initiation of
breast cancer therapy with possible consequences to the bone
homeostasis. Various guidelines exist with algorithms to eval-
uate individual fragility profile and treatment with antiresorp-
tive therapy [45]. These are in accord as concerns the
assumption of all risk factors, but recommend intervention
with different agents and at different BMD thresholds.
In conclusion, adjuvant treatment in breast cancer may
exert an adverse effect on the BMD and the risk of fracture,
which should be monitored during therapy. Estrogen depriva-
tion in particular should be handled with care at the start of the
treatment and regularly thereafter. Long-term results with
bisphosphonates and the promising data with denosumab
indicate that their administration support the integrity of the
bone by maintaining or even improving it during adjuvant
endocrine therapy.
Adjuvant Anti-Bone Resorptive Therapy
for the Prevention of Relapse in High-Risk
Breast Cancer Patients
As previously detailed, during bone degradation and active
bone remodeling, various growth factors and enzymes are
released which may support the growth of tumor cells and the
progression of the cancer. Hence, the blockade of this complex
process by bone-targeted anti-resorptive agents is expected to
inhibit cancer growth. The rate of bone loss is dramatically
accelerated by ovarian ablation in premenopausal women and
AI therapy in postmenopausal women. Both preclinical and
clinical research data point to the possible tumor inhibitory
effects of anti-bone resorptive agents (Table 6).
In two pilot studies involving high-risk breast cancer
patients, disseminated tumor cells were cleared from the bone
marrow by the administration of zoledronate [47]. Two early
studies with a long follow-up demonstrated significant
disease-free survival (DFS) and overall survival (OS) benefit
after adjuvant clodronate therapy [47, 49]. The AZURE study
evaluated the effects of zoledronate combined with chemo-
therapy and hormone therapy in a population of premeno-
pausal and postmenopausal women [48]. In the overall study
population there was no difference in DFS, whereas OS
indicated a trend toward a better outcome in patients treated
with zoledronate. Nonetheless, prospective subgroup analysis
Table 6 Adjuvant bisphosphonate therapy in breast cancer
Study n Schedule FU HR overall HR postmenopausal subgroup
Powles 2004 [46] 1069 clodronate 1,600 mg, 2 years 5 years 0.692 (p00.043) (bone)
Diel 1998 [47] 302 clodronate 1,600 mg, 2 years 53 months p<0.001
ABCSG-12 [35] 3360 zoledronate 4 mg, 6 months 5 years 0.68 (p00.009) NA
AZURE [48] 3539 zoledronate 4 mg, 1-3-6 months 59 months NS 0.76 (p<0.05)
Z-FAST [36] 602 zoledronate 4 mg, 6 months 54 months NS NA
ZO-FAST [37] 1066 zoledronate 4 mg, 6 months 48 months 0.66 (p00.0375) NA
E-ZO-FAST [38] 527 zoledronate 4 mg, 6 months 59 months NS NA
FU follow-up, HR hazard ratio, NS not significant; NA not appropriate
Table 7 Clinical studies on bisphosphonates as breast cancer prevention therapy
Study Design Therapy Breast cancer risk
Breast cancer Northern Israel
Study (Rennert 2010 [54])
case–control study, n04039
>50-year-old postmenopausal women
bisphosphonate >1 year
(mostly alendronate)
0.72 (0.57−0.90)
WHI (Chlebowski 2010 [55]) WHI cohort, n02816 bisphosphonate
user/total n0154768 >50-year-old women
clodronate/alendronate,
FU093 months
0.70 (0.52−0.94) ER + BC:
0.68 (0.52−0.88)
FU follow-up
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according to the menopausal status revealed a significant
benefit of zoledronate in terms of DFS and OS if the patient
had passed the menopause at least 5 years before the com-
mencement of therapy.Within the AZURE study, 205 patients
received neoadjuvant chemotherapy with or without zoledro-
nate [50]. In this subgroup analysis, the primary endpoint was
the residual invasive tumor size after surgery. The patients in
the zoledronate arm exhibited a significantly greater response
to treatment.
The ABCSG-12 study was designed to investigate the
effects of zoledronate on survival in a population of 1,803
premenopausal breast cancer patients treated with combined
endocrine therapy with or without zoledronate. The primary
endpoint was a DFS. The administration of zoledronate was
associated with a 32 % improvement in DFS after a follow-up
time of 5 years, and interestingly, all distant metastasis sites
and also locoregional recurrence rates were decreased by the
intervention. The benefit in OS reached statistical significance
after a median follow-up time of 76 months [35].
The aim of the Z-FAST, ZO-FAST and E-ZO-FAST
companion trials was to evaluate the potential of zoledronate
to prevent AI-induced bone loss in postmenopausal patients
treated with letrozole. Among these studies, only the ZO-
FAST trial, which was appropriately powered to detect a
significant difference in events between the treatment arms,
revealed such a potential (Table 6).
The randomized controlled adjuvant zoledronate studies
were subjected to meta-analysis by Yan et al. [51]. This
demonstrated that, while adjuvant zoledronate did not im-
prove the survival in the overall population, in the subgroup
of postmenopausal patients the addition of zoledronic acid
to the standard therapy improved DFS, and decreased the
risk of distant or locoregional recurrence (RR00.763, p<
0.001, RR00.744, p00.003, RR00.508, p00.001, respec-
tively). The anticancer activity zoledronate is restricted to
patients with a low estrogen level: the inhibition of en-
hanced bone remodeling results in the blockade of cancer
stimulation. Accordingly, the monoclonal antibody denosu-
mab, which is also able to influence the bone microenviron-
ment, is under investigation as potential adjuvant therapy in
high-risk breast cancer patients (Table 6) [52].
Breast Cancer Prevention
The prevention of breast cancer in healthy individuals implies
intervention in those at high risk of developing breast cancer.
Besides life style changes and diet, the options studied for
prevention include medical therapy traditionally referred to as
called chemoprevention, but the expression breast cancer
prevention has recently been concluded to be more appropri-
ate nomenclature [53]. The medical therapy that has been
studied includes the anti-estrogens, the estrogen depletion
methods, e.g. involving AIs or LHRH analogs, the statins,
the COX-2 inhibitors, metformin and the bisphosphonates.
Two relatively large studies that made use of pharmacy
records or data from self-questionnaires in populations under-
going breast screening showed that in patients treated with
bisphosphonates, the risk of breast cancer was reduced by
about 30 % (Table 7). One study suggested a reduction in the
number of estrogen receptor-negative breast cancers [54], and
the other a reduction in the number of estrogen receptor-
positive breast cancers [55]; the difference may be a result of
differences in lifestyle and genetics between the two popula-
tions. These results are in consistence with those which point to
bisphosphonates’ direct antitumor activity. This potential could
be more fully utilized if the rapid clearance of bisphosphonates
from the circulation due to their pharmacokinetic features were
prevented. New nanotechnology formulations such as liposo-
mal and pegylated liposomal zoledronate show enhanced tu-
mor inhibitory effects. In addition to the long-lasting presence
of zoledronate resulting in higher extraskeletal bioavailability,
the size of the nanoparticles favoring selective uptake by the
tumor might explain increased efficiency [56, 57].
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